Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors.

导出 OA

翻译打印收藏纠错

作者： Sebastian M,Dieter ^[1] ; Domenica,Lovecchio ^[2] ; Abhijeet,Pataskar ^[3] ; Martina K,Zowada ^[4] ; Pierre-René,Körner ^[5] ; Anna,Khalizieva ^[5] ; Olaf,van Tellingen ^[6] ; Dirk,Jäger ^[5] ; Hanno,Glimm ^[5] ; Reuven,Agami ^[7]

作者单位： Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. s.dieter@nki.nl. ^[1] Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany. s.dieter@nki.nl. ^[2] Department of Medical Oncology, Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany. s.dieter@nki.nl. ^[3] Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), Dresden, Germany. s.dieter@nki.nl. ^[4] Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[5] Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[6] Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[7] Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Dresden and German Cancer Research Center (DKFZ), Dresden, Germany. ^[8] German Cancer Consortium (DKTK), Heidelberg, Germany. ^[9] Department of Medical Oncology, Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany. ^[10] Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus Dresden at TU Dresden, Dresden, Germany. ^[11] German Cancer Consortium (DKTK), Dresden, Germany. ^[12] Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.agami@nki.nl. ^[13] Erasmus MC, Rotterdam University, Rotterdam, The Netherlands. r.agami@nki.nl. ^[14]